71 related articles for article (PubMed ID: 9116295)
1. Frequent hypermethylation of p16 and p15 genes in multiple myeloma.
Ng MH; Chung YF; Lo KW; Wickham NW; Lee JC; Huang DP
Blood; 1997 Apr; 89(7):2500-6. PubMed ID: 9116295
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of glioma cell lines for p16, p15, p53 and p21 gene alterations.
Zhang S; Endo S; Koga H; Ichikawa T; Feng X; Onda K; Washiyama K; Kumanishi T
Jpn J Cancer Res; 1996 Sep; 87(9):900-7. PubMed ID: 8878451
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy for multiple myeloma: an overview on CD138-based strategies.
Riccardi F; Tangredi C; Dal Bo M; Toffoli G
Front Oncol; 2024; 14():1370854. PubMed ID: 38655136
[TBL] [Abstract][Full Text] [Related]
4. CIP/KIP and INK4 families as hostages of oncogenic signaling.
Csergeová L; Krbušek D; Janoštiak R
Cell Div; 2024 Apr; 19(1):11. PubMed ID: 38561743
[TBL] [Abstract][Full Text] [Related]
5. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells.
Pelon M; Krzeminski P; Tracz-Gaszewska Z; Misiewicz-Krzeminska I
Front Pharmacol; 2024; 15():1351565. PubMed ID: 38500772
[TBL] [Abstract][Full Text] [Related]
6. The Role of Epigenetics in the Development and Progression of Multiple Myeloma.
Ismail NH; Mussa A; Zakaria NA; Al-Khreisat MJ; Zahidin MA; Ramli NN; Mohammad SNNA; Hassan R; Mohd Noor NH; Iberahim S; Zulkafli Z; Mohamed Yusoff S; Husin A; Johan MF
Biomedicines; 2022 Oct; 10(11):. PubMed ID: 36359286
[TBL] [Abstract][Full Text] [Related]
7. Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Muylaert C; Van Hemelrijck LA; Maes A; De Veirman K; Menu E; Vanderkerken K; De Bruyne E
Front Oncol; 2022; 12():979569. PubMed ID: 36059621
[TBL] [Abstract][Full Text] [Related]
8. The epigenetic impact of suberohydroxamic acid and 5‑Aza‑2'‑deoxycytidine on DNMT3B expression in myeloma cell lines differing in IL‑6 expression.
Trtkova KS; Luzna P; Drozdkova DW; Cizkova K; Janovska L; Gursky J; Prukova D; Frydrych I; Hajduch M; Minarik J
Mol Med Rep; 2022 Oct; 26(4):. PubMed ID: 36043519
[TBL] [Abstract][Full Text] [Related]
9. Cyclin-dependent kinase inhibitors in malignant hematopoiesis.
Schirripa A; Sexl V; Kollmann K
Front Oncol; 2022; 12():916682. PubMed ID: 36033505
[TBL] [Abstract][Full Text] [Related]
10. Genome Instability in Multiple Myeloma: Facts and Factors.
Aksenova AY; Zhuk AS; Lada AG; Zotova IV; Stepchenkova EI; Kostroma II; Gritsaev SV; Pavlov YI
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885058
[TBL] [Abstract][Full Text] [Related]
11. A Comprehensive Review of the Genomics of Multiple Myeloma: Evolutionary Trajectories, Gene Expression Profiling, and Emerging Therapeutics.
Awada H; Thapa B; Awada H; Dong J; Gurnari C; Hari P; Dhakal B
Cells; 2021 Aug; 10(8):. PubMed ID: 34440730
[TBL] [Abstract][Full Text] [Related]
12. Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma.
Barwick BG; Gupta VA; Matulis SM; Patton JC; Powell DR; Gu Y; Jaye DL; Conneely KN; Lin YC; Hofmeister CC; Nooka AK; Keats JJ; Lonial S; Vertino PM; Boise LH
Clin Cancer Res; 2021 Jun; 27(11):3178-3189. PubMed ID: 33731366
[TBL] [Abstract][Full Text] [Related]
13. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma.
Barwick BG; Gupta VA; Vertino PM; Boise LH
Front Immunol; 2019; 10():1121. PubMed ID: 31231360
[TBL] [Abstract][Full Text] [Related]
14. The therapeutic potential of cell cycle targeting in multiple myeloma.
Maes A; Menu E; Veirman K; Maes K; Vand Erkerken K; De Bruyne E
Oncotarget; 2017 Oct; 8(52):90501-90520. PubMed ID: 29163849
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance of the
Yu H; Yang L; Fu Y; Gao M; Tian L
Oncotarget; 2017 Oct; 8(47):83270-83279. PubMed ID: 29137341
[TBL] [Abstract][Full Text] [Related]
16. Recurrent alterations of the WW domain containing oxidoreductase gene spanning the common fragile site FRA16D in multiple myeloma and monoclonal gammopathy of undetermined significance.
Handa H; Sasaki Y; Hattori H; Alkebsi L; Kasamatsu T; Saitoh T; Mitsui T; Yokohama A; Tsukamoto N; Matsumoto M; Murakami H
Oncol Lett; 2017 Oct; 14(4):4372-4378. PubMed ID: 28943951
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic strategies to reverse drug resistance in heterogeneous multiple myeloma.
Issa ME; Takhsha FS; Chirumamilla CS; Perez-Novo C; Vanden Berghe W; Cuendet M
Clin Epigenetics; 2017; 9():17. PubMed ID: 28203307
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological significance of p15 promoter hypermethylation in multiple myeloma: a meta-analysis.
Wei B; Yang S; Zhang B; Feng Y
Onco Targets Ther; 2016; 9():4015-22. PubMed ID: 27445492
[TBL] [Abstract][Full Text] [Related]
19. A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: results from the IMMEnSE consortium and meta-analysis.
Ríos-Tamayo R; Lupiañez CB; Campa D; Hielscher T; Weinhold N; Martínez-López J; Jerez A; Landi S; Jamroziak K; Dumontet C; Wątek M; Lesueur F; Reis RM; Marques H; Jurczyszyn A; Vogel U; Buda G; García-Sanz R; Orciuolo E; Petrini M; Vangsted AJ; Gemignani F; Försti A; Goldschmidt H; Hemminki K; Canzian F; Jurado M; Sainz J
Oncotarget; 2016 Sep; 7(37):59029-59048. PubMed ID: 27437873
[TBL] [Abstract][Full Text] [Related]
20. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells.
Das DS; Ray A; Das A; Song Y; Tian Z; Oronsky B; Richardson P; Scicinski J; Chauhan D; Anderson KC
Leukemia; 2016 Nov; 30(11):2187-2197. PubMed ID: 27118403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
